NCT00928330View on ClinicalTrials.gov

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Metastatic Breast Cancer
Interventions
DRUG

GDC-0941

Oral repeating dose

DRUG

Trastuzumab

Intravenous repeating dose

DRUG

trastuzumab-MCC-DM1

Intravenous repeating dose

Trial Locations (3)

21231

Baltimore

46202

Indianapolis

02115

Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00928330 - Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | Biotech Hunter | Biotech Hunter